// App-Quantinova.ai

2057 : Non-Interventional Study Hexafil: G-CSF Use in Accordance to Guidelines?

Researchers

Presenter

  • Wolfgang Abenhardt

Principal Investigators

  • Lutz Dietze

  • DeLi Tilly Chang

  • Bertram Ottillinger

Medical Centers

  • Bethanien Hospital, Frankfurt am Main, Germany,

  • Haematology-oncology group practice, Cologne, Germany

  • Munchner Onkologische Praxis, Munchen, Germany

  • Ottillinger Life Sciences, Hofolding, Germany

Locations

  • Germany

Companies

  • Hexal AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Gynaecological cancer

  • Breast cancer

  • Lung Cancer

  • Neutropenia

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Granulocyte colony-stimulating factor

  • Chromosomal instability

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Adrucil injection

  • Fluorouracil

  • Doxorubicin

  • Epirubicin

  • Filgrastim

  • Docetaxel

  • Filgrastim-Sndz

  • Sandolase

Outcome

  • N/A

Study Design

  • observational

  • non interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved